Navigation Links
MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
Date:7/1/2008

Pioneer in Centralized Psychiatric Patient Evaluation for Clinical Trials

Expanding Into New Areas of Drug Development

HAMILTON, N.J., July 1 /PRNewswire/ -- MedAvante, Inc., the leader in centralized psychiatric patient evaluation, announced today that it has closed a $20 million financing by Goldman, Sachs & Co. and Trevi Health Ventures. MedAvante has developed an innovative platform to centralize and calibrate the assessment of patients undergoing treatment in clinical trials in order to more reliably and precisely measure their response to therapies. MedAvante currently provides centralized patient evaluation services to many of the world's largest pharmaceutical companies with central nervous system drug candidates, and has administered more than 21,000 remote expert assessments for Phase 2 and Phase 3 large pharma studies including acute schizophrenia, major depressive disorder, generalized anxiety disorder, and psychotic depression.

The Company will use the capital to fund the expansion of its existing patient evaluation platform to meet increasing demand from pharmaceutical companies. The capital will also enable MedAvante to apply its platform into new areas of drug development, including monitoring by mental health professionals of potential warning signs for suicide. The U.S. Food and Drug Administration (FDA) is requiring most drugs with centrally acting mechanisms to be assessed for suicidality, regardless of whether the drugs are being developed for neurological or psychiatric indications.

"The investment by Goldman Sachs and Trevi Health gives MedAvante the capital and resources to deliver on our mission of helping the life sciences industry bring better and safer drugs to patients faster," stated Paul Gilbert, Chief Executive Officer of MedAvante. Gilbert further noted, "Our unique ability to centralize and standardize the assessment of psychiatric patient's disease severity and progression is transforming
'/>"/>

SOURCE MedAvante, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Markets and Companies" to their offering. ... markets based on technologies and applications. The report ... basis for estimation of markets. Technologies include array ...
(Date:9/2/2015)... 02, 2015 ... announced the addition of Jain PharmaBiotech,s new ... Companies" to their offering. ... besides fluorescence in situ hybridization (FISH), comparative ... cytogenetics includes application of nanobiotechnology, microarrays, real-time ...
(Date:9/2/2015)... , Sept. 2, 2015 Australian prostate ... a prestigious Australian science prize recognising ,outstanding, science that ... track to globally launch a novel prostate cancer diagnostic ... a high level consortium taking out the peer-reviewed Australian ... Scientific Research. This prize is awarded ...
(Date:9/2/2015)... ZIONA, Israel , September 2, ... TASE: BVXV) today announced the intent of the National Institute ... National Institutes of Health (NIH) within the Department of Health ... trial to be held in the United States ... the use of BiondVax,s universal flu vaccine candidate, Multimeric-001 (M-001), ...
Breaking Biology Technology:Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 2Prostate Cancer Company Minomic Wins Prestigious Eureka Science Prize 3BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3
... Oct. 29 MannKind,Corporation (Nasdaq: MNKD ) will ... 5, 2008 at 8:00 a.m. EST., Management of ... the,third quarter financial results, clinical progress and other Company,developments ... from the,Company will be its Chairman and Chief Executive ...
... (Nasdaq: SGMO ) today reported third quarter 2008,financial ... September 30, 2008, Sangamo reported a,consolidated net loss of ... loss of $4.3 million, or $0.11 per share, for ... the company had cash, cash equivalents and,investments of $59.5 ...
... Pharmaceuticals Inc.,(Nasdaq: TRBN ) today announced that executives ... at two upcoming industry and/or investor,conferences:, -- Nov. ... the,New York Palace Hotel, 455 Madison Ave. in New ... president, is scheduled to present,at 9:55 a.m. EST., ...
Cached Biology Technology:MannKind Corporation to Hold Third Quarter Financial Results Conference Call on November 5, 2008 2Sangamo BioSciences Reports Third Quarter 2008 Financial Results 2Sangamo BioSciences Reports Third Quarter 2008 Financial Results 3Sangamo BioSciences Reports Third Quarter 2008 Financial Results 4Sangamo BioSciences Reports Third Quarter 2008 Financial Results 5Sangamo BioSciences Reports Third Quarter 2008 Financial Results 6Sangamo BioSciences Reports Third Quarter 2008 Financial Results 7Trubion Announces Presentations at Upcoming Investor Conferences 2
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/4/2015)... 2015 Research ... the addition of the "Digital Forensics ... Sub-Segment (Computer Forensics, Network Forensics, Mobile Device ... Vertical and Region - Global Forecast to ... By Component (Hardware, Software, and Service), ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... gene they suspect plays an important role in triggering ... century-and-a-half ago. , And the pathogen that contains this ... the modern world?on the order of billions of dollars ... Avr3a, in a study that appears online in the ...
... Created as an alternate route of drug administration to ... skin patches are rapidly becoming an important healthcare product ... of chronic conditions such as angina, hypertension and HRT, ... transdermal patches for a host of new conditions wind ...
... Microarray technology can be used to identify each stage ... newly published report. , Melanomas grow in two phases: ... metastasize (spread cancer to other parts of the body) ... a large primary melanoma into radial and vertical portions, ...
Cached Biology News:Researchers find gene that may be at root of potato blight 2Researchers find gene that may be at root of potato blight 3
... ISO 9001:2000 Certified USDA Research Registered OLAW ... Training AALAS Certified Technicians ... GLP Documentation Upon Request Focus ... for all your custom immunology service needs. ...
biotin-4-fluorescein...
Human IL-17D Affinity Purified Polyclonal Ab...
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: